POTENTIAL OF ETHANOL EXTRACT OF MAHKOTA DEWA LEAVES (PHALERIA MACROCARPA (SCHECFF.) BOERL.) TO INHIBIT INFLAMMATION IN MOUSE DISTAL COLON INDUCED BY DEXTRAN SODIUM SULFATE (DSS) AND AZOXYMETHANE (AOM)
Objective: To demonstrates the ability of P. macrocarpa leaf extract to reduce inflammation of the distal colon in DSS/AOM-induced mice.
Methods: In vivo experimental research using Balb/c mice induced by 0.2 ml azoxymethane (AOM) 0.1% once and 1% dextran sodium sulphate (DSS) for one week; additionally, ethanol extract of P. macrocarpa leaves, 25 mg and 50 mg, and 0.84 mg acetosal were given orally. The mice were sacrificed after 20 w. Histopathological examination (hematoxylin-eosin staining) was conducted by counting the average number of goblet cells per crypt, inflammatory focus and angiogenesis.
Results: Ethanol extract of P. macrocarpa leaves was able to prevent the decrease in the number of goblet cells (p<0.05). However, the administration of ethanol P. macrocarpa leaf extract could not reduce focal inflammation and angiogenesis in inflammation of the distal colon.
Conclusion: Ethanol extract of the Mahkota Dewa leaves is able to prevent inflammation of the distal colon by preventing the decrease in the number of goblet cells.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713–25.
3. Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol 2009;21:1–8.
4. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313–23.
5. Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis 2009;27:455–64.
6. Hauso Ø, Martinsen TC, Waldum H. 5-aminosalicylic acid, a specific drug for ulcerative colitis. Scand J Gastroenterol 2015;50:933–41.
7. Cottone M, Renna S, Modesto I, Orlando A. Is 5-ASA still the treatment of choice for ulcerative colitis? Curr Drug Targets 2011;12:1396–405.
8. Altaf R, Asmawi MZB, Dewa A, Sadikun A, Umar MI. Phytochemistry and medicinal properties of Phaleria macrocarpa (Scheff.) Boerl. extracts. Pharmacogn Rev 2013;7:73–80.
9. Dharmani P, Srivastava V, Kissoon Singh V, Chadee K. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2009;1:123–35.
10. McGuckin MA, Eri R, Simms LA, Florin TH, Radford Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100–13.
11. Shirazi T, Longman R, Corfield A, Probert C. Mucins and inflammatory bowel disease. Postgrad Med J 2000;76:473–8.
12. Longman RJ, Poulsom R, Corfield AP, Warren BF, Wright NA, Thomas MG. Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem 2006;54:1335–48.
13. Dorofeyev AE, Vasilenko IV, Rassokhina OA, Kondratiuk RB. Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol Res Pract 2013. DOI:10.1155/2013/431231
14. Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, Herrlinger KR, et al. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009;77:84–94.
15. Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, et al. A guide to the histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol 2014;7:4557–76.
16. Maharani R, Kusmardi, Elya B. Inhibitory activity goblet depletion and focal inflammatory Phaleria macrocarpha leaves ethanol extract on crypta mouse after dextran sodium sulphate induction. Int J Pharmtech Res 2018;12:37–48.
17. Greenson JK, Stern RA, Carpenter SL, Barnett JL. The clinical significance of focal active colitis. Hum Pathol 1997;28:729–33.
18. Osmond A, Ashok D, Francoeur CA, Miller M, Walsh JC. Is focal active colitis of greater clinical significance in pediatric patients? a retrospective review of 68 cases with clinical correlation. Hum Pathol 2018;74:164–9.
19. Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon Rombi C, Peyrin-Biroulet L. Comparing histological activity indexes in UC. Gut 2015;64:1412–8.
20. Suprapti T, Louisa M, Tedjo A, Kusmardi, Fadilah, Handjari DR, et al. Antiinflammatory effect of mahkota dewa (Phaleria macrocarpa (Scheff.) Boerl.) leaves extract on colon carcinogenesis induced by azoxymethane and dextran sodium sulphate: focus on the iNOS, ?-catenin and COX-2 expression. Asian J Appl Sci 2014;2:511–27.
21. Wera O, Lancellotti P, Oury C. The dual role of neutrophils in inflammatory bowel diseases. J Clin Med 2016;5:118.
22. Pousa ID, Mate J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest 2008;38:73–81.
23. Alkim C, Alkim H, Koksal AR, Boga S, Sen I. Angiogenesis in inflammatory bowel disease. Int J Inflam 2015. DOI:10.1155/2015/970890
24. Jerkic M, Peter M, Ardelean D, Fine M, Konerding MA, Letarte M. Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in Endoglin heterozygous mice. Inflamm Bowel Dis 2010;16:1859–70.
25. Chidlow JH, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: New ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007;293:G5–G18.
This work is licensed under a Creative Commons Attribution 4.0 International License.